Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Meloxicam Tablets vs Capsules
NCT02180477Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2001
- Primary completion
- Dec 2001
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of meloxicam in osteoarthritis (OA) and rheumatoid arthritis (RA) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum observed concentration in plasma up to 72 hours and Area under the concentration-time curve in plasma from zero time to 72 hours. Started Nov 2001; status: completed.
02
Drugs
meloxicam
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02180477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02180477.